A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
Offman, Marc N
Moss, Catherine X
Van Delft, Frederik W
Dempsey, Clare E
Eden, Tim O B
Bates, Paul A
AffiliationCancer Research UK Children's Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
MetadataShow full item record
Abstractl-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism. The mechanisms of therapeutic failure with l-asparaginase remain speculative. Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. Cathepsin B (CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli (ASNase) and Erwinia chrysanthemi. Asparaginyl endopeptidase (AEP), which is overexpressed predominantly in high-risk subsets of ALL, specifically degraded ASNase. AEP thereby destroys ASNase activity and may also potentiate antigen processing, leading to allergic reactions. Using AEP-mediated cleavage sequences, we modeled the effects of the protease on ASNase and created a number of recombinant ASNase products. The N24 residue on the flexible active loop was identified as the primary AEP cleavage site. Sole modification at this site rendered ASNase resistant to AEP cleavage and suggested a key role for the flexible active loop in determining ASNase activity. We therefore propose what we believe to be a novel mechanism of drug resistance to ASNase. Our results may help to identify alternative therapeutic strategies with the potential of further improving outcome in childhood ALL.
CitationA dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. 2009, 119 (7):1964-73 J. Clin. Invest.
JournalThe Journal of Clinical Investigation
- Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
- Authors: Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP
- Issue date: 2014 Nov
- Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
- Authors: Rodrigues MAD, Pimenta MV, Costa IM, Zenatti PP, Migita NA, Yunes JA, Rangel-Yagui CO, de Sá MM, Pessoa A, Costa-Silva TA, Toyama MH, Breyer CA, de Oliveira MA, Santiago VF, Palmisano G, Barbosa CMV, Hebeda CB, Farsky SHP, Monteiro G
- Issue date: 2020 Dec
- Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
- Authors: Mondelaers V, Ferster A, Uyttebroeck A, Brichard B, van der Werff Ten Bosch J, Norga K, Francotte N, Piette C, Vandemeulebroecke K, Verbeke C, Schmidt S, Benoit Y, Lammens T, De Moerloose B
- Issue date: 2020 Jul
- Population pharmacokinetics of native Escherichia coli asparaginase.
- Authors: Borghorst S, Pieters R, Kuehnel HJ, Boos J, Hempel G
- Issue date: 2012 Mar
- Novel site-specific PEGylated L-asparaginase.
- Authors: Meneguetti GP, Santos JHPM, Obreque KMT, Barbosa CMV, Monteiro G, Farsky SHP, Marim de Oliveira A, Angeli CB, Palmisano G, Ventura SPM, Pessoa-Junior A, de Oliveira Rangel-Yagui C
- Issue date: 2019